» Articles » PMID: 1399724

The Significance of Post-irradiation Prostate Biopsy with Long-term Follow-up

Overview
Specialties Oncology
Radiology
Date 1992 Jan 1
PMID 1399724
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Ninety-four patients, Stage A2-C, definitively irradiated for adenocarcinoma of the prostate from 1975 to 1981 underwent digitally directed transperineal needle biopsy of a clinically negative prostate gland at least 18 months post-therapy. Ten of 55 patients (18%) treated with Iodine-125 implantation and 7 of 39 patients (18%) externally irradiated were found to have positive biopsy specimens. Overall, clinical local failure occurred in 53% of patients with positive biopsy results but in only 18% with negative specimens, p = .006. The false negative biopsy rate in patients treated with I-125 was nearly three times that for external beam, 24% versus 9%, perhaps because of the greater possibility of inhomogeneous dose distribution with I-125, allowing for a higher degree of sampling error. Actuarial local failure at 5 years was 44% versus 8% with positive and negative biopsies, respectively, and 75% versus 24% at 10 years (p = .0001). The distant metastatic rate was twice as high in biopsy-positive as compared to biopsy-negative patients, 71% versus 35%, p = .015. Actuarially, only 19% of patients with a positive biopsy are NED at 10 years as compared to 62% of those with a negative biopsy (p = .0001). PSA values are supportive in those patients thought to be disease-free. The incidence of positive biopsy and associated local recurrence are in keeping with clinical treatment failure rates as reported in multiple studies to date.

Citing Articles

Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

McGee K, Hwang K, Sullivan D, Kurhanewicz J, Hu Y, Wang J Med Phys. 2021; 48(7):e697-e732.

PMID: 33864283 PMC: 8361924. DOI: 10.1002/mp.14884.


Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer.

Freytag S, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D Int J Radiat Oncol Biol Phys. 2014; 89(2):268-76.

PMID: 24837889 PMC: 4026796. DOI: 10.1016/j.ijrobp.2014.02.034.


The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang V, Westphalen A, Delos Santos L, Tabatabai Z, Shinohara K, Vigneron D NMR Biomed. 2013; 27(1):100-11.

PMID: 23940096 PMC: 3864570. DOI: 10.1002/nbm.3007.


Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.

Brawer M Rev Urol. 2006; 4 Suppl 2:S2-S11.

PMID: 16986008 PMC: 1477545.


[Pelvic laparoscopic lymphadenectomy after definitive radiotherapy of prostatic carcinoma].

Dinges S Strahlenther Onkol. 1998; 174(7):386-7.

PMID: 9689965 DOI: 10.1007/BF03038358.